Outcome of Board Meeting dated 15th October 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Yash Chemex's board approved its Q2 and H1 FY26 (ended 30 Sept 2025) un-audited financial results on 15 October 2025. Standalone revenue from operations surged to Rs. 2,255.96 lakhs in Q2 (up ~45% YoY from Rs. 1,553.40 lakhs) and Rs. 4,030.59 lakhs for H1 (up ~72% YoY). Consolidated revenue from operations grew to Rs. 3,864.75 lakhs in Q2 (~58% YoY) and Rs. 6,875.21 lakhs in H1 (~81% YoY), driven by subsidiary Yasons Chemex Care Limited. However, profitability lagged: standalone net profit was Rs. 46.19 lakhs in Q2 (down ~11% YoY) and Rs. 75.85 lakhs in H1 (flat YoY), while consolidated net profit declined to Rs. 91.37 lakhs in Q2 and Rs. 177.17 lakhs in H1 (down ~24% YoY), reflecting margin compression from rising input and operating costs. The statutory auditor S. L. Patel & Co. issued an unmodified (clean) limited review opinion on both sets of results.
Strong top-line growth is a positive, but shrinking bottom-line and significant margin compression signal rising cost pressures that investors should watch. The negative consolidated operating cash flow of Rs. 106.36 lakhs in H1 indicates working-capital strain despite higher sales, which may temper near-term optimism.